2024
Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Xu F, Hui P, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses. Gynecologic Oncology 2024, 190: s299-s301. DOI: 10.1016/j.ygyno.2024.07.449.Peer-Reviewed Original ResearchRandomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMID: 39516558, PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.Peer-Reviewed Original ResearchPre-treated ovarian cancerOverall survivalBev armsDose reductionOvarian cancerTaxane responseRandomized phase 2 trialRandomized phase II trialPaclitaxel-resistant diseaseResultsThirty-seven patientsTreated with paclitaxelPhase 2 trialBiweekly bevacizumabDays 1,8,15Taxane-sensitiveUpdate survivalProgression-freePeritoneal cancerDose modificationTaxane sensitivityPlatinum resistanceSubset analysisSubgroup analysisResponse ratePatients
2019
Pseudovascular Invasion: Minimally Invasive Surgery for Endometrial Cancer
Seifi F, Parkash V, Clark M, Menderes G, Tierney C, Silasi DA, Azodi M. Pseudovascular Invasion: Minimally Invasive Surgery for Endometrial Cancer. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2019, 23: e2019.00021. PMID: 31285650, PMCID: PMC6596444, DOI: 10.4293/jsls.2019.00021.Peer-Reviewed Original ResearchConceptsLymphovascular space invasionEndometrial cancerSpace invasionEarly-stage endometrial cancerPatients meeting eligibility criteriaInvasive surgical stagingStage endometrial cancerRetrospective cohort studyBody mass indexMeeting eligibility criteriaPeritoneal cytologyAdjuvant radiotherapyAdjuvant therapyAdjuvant treatmentSurgical stagingCohort studyLymphovascular invasionSerous histologyPathologic evaluationMass indexGynecologic pathologistsSubgroup analysisTumor gradeUterine manipulatorIntrauterine manipulator